Balance Sheet
Cash Flow Statement
Beginning Cash BalanceChange in Account PayablesCurrent DebtGains from Sales and DivestituresNet Debt Issuances and RepaymentsNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Gains from Sales and Divestitures: 2023-2024

Historic Gains from Sales and Divestitures for China SXT Pharmaceuticals (SXTC) over the last 2 years, with Mar 2024 value amounting to $8.0 million.

  • China SXT Pharmaceuticals' Gains from Sales and Divestitures rose 1249.18% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 million, marking a year-over-year increase of 1249.18%. This contributed to the annual value of $8.0 million for FY2024, which is 39.90% up from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $8.0 million for FY2024, which was up 39.90% from $5.7 million recorded in FY2023.
  • In the past 5 years, China SXT Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $8.0 million in FY2024 and a low of $5.7 million during FY2023.
  • Over the past 2 years, China SXT Pharmaceuticals' median Gains from Sales and Divestitures value was $6.9 million (recorded in 2023), while the average stood at $6.9 million.
  • Data for China SXT Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY spiked of 39.90% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows China SXT Pharmaceuticals' Gains from Sales and Divestitures stood at $5.7 million in 2023, then soared by 39.90% to $8.0 million in 2024.